Salerno Silvia, Barresi Elisabetta, Baglini Emma, Poggetti Valeria, Taliani Sabrina, Da Settimo Federico
Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
Biomedicines. 2022 Nov 15;10(11):2932. doi: 10.3390/biomedicines10112932.
Topoisomerase (Topo) inhibitors have long been known as clinically effective drugs, while G-quadruplex (G4)-targeting compounds are emerging as a promising new strategy to target tumor cells and could support personalized treatment approaches in the near future. G-quadruplex (G4) is a secondary four-stranded DNA helical structure constituted of guanine-rich nucleic acids, and its stabilization impairs telomere replication, triggering the activation of several protein factors at telomere levels, including Topos. Thus, the pharmacological intervention through the simultaneous G4 stabilization and Topos inhibition offers a new opportunity to achieve greater antiproliferative activity and circumvent cellular insensitivity and resistance. In this line, dual ligands targeting both Topos and G4 emerge as innovative, efficient agents in cancer therapy. Although the research in this field is still limited, to date, some chemotypes have been identified, showing this dual activity and an interesting pharmacological profile. This paper reviews the available literature on dual Topo inhibitors/G4 stabilizing agents, with particular attention to the structure-activity relationship studies correlating the dual activity with the cytotoxic activity.
拓扑异构酶(Topo)抑制剂长期以来一直被认为是临床有效的药物,而靶向G-四链体(G4)的化合物正作为一种有前景的靶向肿瘤细胞的新策略出现,并可能在不久的将来支持个性化治疗方法。G-四链体(G4)是一种由富含鸟嘌呤的核酸构成的二级四链DNA螺旋结构,其稳定化会损害端粒复制,触发端粒水平上几种蛋白因子的激活,包括拓扑异构酶。因此,通过同时稳定G4和抑制拓扑异构酶进行药理干预,为实现更大的抗增殖活性以及规避细胞不敏感性和耐药性提供了新机会。在这方面,同时靶向拓扑异构酶和G4的双功能配体成为癌症治疗中创新、高效的药物。尽管该领域的研究仍然有限,但迄今为止,已经鉴定出一些化学类型,显示出这种双重活性和有趣的药理特性。本文综述了关于双功能拓扑异构酶抑制剂/G4稳定剂的现有文献,特别关注将双重活性与细胞毒性活性相关联的构效关系研究。